Bag1 directly routes immature BCR-ABL for proteasomal degradation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chronic myelogenous leukemia (CML) treatment often involves ABL tyrosine kinase inhibitors.
• Resistance to these inhibitors can develop, necessitating alternative therapeutic strategies.
• Heat shock protein 90 (Hsp90) inhibitors are being investigated to overcome resistance by targeting BCR-ABL oncoproteins.

Purpose of the Study:

• To elucidate the precise mechanisms by which Hsp90 inhibitors induce BCR-ABL degradation.
• To identify the roles of specific E3 ligases and associated proteins in this process.
• To explore potential therapeutic strategies for overcoming resistance in CML.

Main Methods:

• Investigated the degradation of BCR-ABL proteins using Hsp90 inhibitors in CML models.
• Utilized knockdown experiments for E3 ligases (c-Cbl, CHIP) and Bag1.
• Analyzed protein-protein interactions using binding assays and assessed proteasomal degradation pathways.

Main Results:

• c-Cbl mediated degradation of mature, phosphorylated BCR-ABL.
• CHIP (carboxyl terminus of the Hsc70-interacting protein) degraded immature BCR-ABL and suppressed leukemic growth.
• Bag1 (Bcl-2-associated athanogene-1) binding to BCR-ABL, enhanced by CHIP and Hsp90 inhibitors, was crucial for Hsp90 inhibitor-induced degradation and proteasomal targeting.

Conclusions:

• CHIP and Bag1 play distinct but cooperative roles in the degradation of BCR-ABL proteins.
• CHIP targets newly synthesized, Hsp90-unchaperoned BCR-ABL to proteasomal degradation, potentially via Bag1.
• Bag1 acts as a key mediator in directing BCR-ABL to degradation pathways, offering a novel therapeutic target for CML.